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deﬁned as activation (Fig. 1), that enables them to acquire a
myoﬁbroblastic phenotype. The biological actions of myoﬁbro-
blasts are pivotal for liver tissue repair and ﬁbrogenesis [1].
(2) Activation of TGFb-dependent ﬁbrogenic signalling in
hepatic stellate cells. The source of TGFb is initially paracrine
including hepatocytes, Kupffer cells, and platelets activated in
response to hepatic injury [2].
(3) At the same time TLR4 signalling in hepatic stellate cells is
required for down-regulation of TGFb pseudoreceptor (and inhib-
itor) BAMBI in order to render hepatic stellate cells sensitive to
TGFb signalling. Bacterial-derived LPS is currently considered to
be the key ﬁbrogenic TLR4 ligand; however, additional endoge-
nous ligands from damaged and dying hepatocytes cannot yet
be ruled out as playing a role [3].
(4) TGFb signals generate transcriptional active pro-ﬁbrogenic
Smad2 and Smad3 complexes [2], but also stimulates collagen
transcription in hepatic stellate cells via hydrogen peroxide
and C/EBPb.
(5) Transcription factors Sp1 and KLF6 stimulate TGFb gene
transcription in hepatic stellate cells to provide autocrine ﬁbro-
genic signalling.
(6) Accumulation of ﬁbrillar matrix is facilitated by increased
expression of tissue inhibitors of metalloproteinases (TIMPs).
(7) Agonists of the nuclear receptor PPARc oppose TGFb sig-
nalling by inhibiting activation of hepatic stellate cells and colla-
gen expression. PPARc expression is diminished during activation
of hepatic stellate cells by an epigenetic mechanism involving the
methylCpG binding protein MeCP2. Ongoing clinical trials with
PPARc agonists will determine their efﬁcacy as anti-ﬁbrotics [4].
(8) Kupffer cells and damaged hepatocytes generate reactive
oxygen species (ROS) [5] which stimulate hepatic stellate cell
expression of chemokines and ampliﬁcation of inﬂammation by
an NF-jB-dependent pathway.
(9) Paracrine and autocrine PDGF signalling [1,5] via PI3
Kinase and ERK serves to perpetuate hepatic stellate cell activa-Journal of Hepatology 20
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Marra).tion, stimulate proliferation to increase the numbers of hepatic
ﬁbrogenic cells, and promote migration to sites of injury.
(10) Hepatic stellate cells express all components of a local
renin–angiotensin system leading to the secretion of Angioten-
sin II (AngII) [5] and its interaction with the AT1 receptor
expressed at the surface of the hepatic stellate cell.
(11) AngII stimulates DNA synthesis, hepatic stellate cell
migration, contraction, collagen production, and secretion of
TGFb by triggering NADPH oxidase (NOX)-generated reactive
oxygen species. ACE inhibitors and/or AT1 receptor antagonists
are shown in experimental models and proof-of-concept clinical
trials to be strong candidates for use in the prevention of liver
ﬁbrosis [5].
(12) Activated hepatic stellate cells express cannabinoid
receptors (CB1 and CB2) [6]. CB2 is anti-ﬁbrogenic, whereas
CB1 is pro-ﬁbrogenic, stimulating phosphorylation of ERK and
Akt to promote proliferation and apoptosis, respectively.
(13) Hepatic stellate cells express receptors for the adipokine
leptin and respond to paracrine and autocrine sources of leptin
[7] by increasing a variety of ﬁbrogenic characteristics including
cell proliferation and survival via NOX-mediated activation of
PI3K and ERK, up-regulation of collagen deposition, and suppres-
sion of matrix metalloproteinase (MMP) activity.
(14) Increased expression of MMPs is a critical event in the
process of ﬁbrosis reversal [8], and macrophage populations
contribute to MMP expression.
(15) Hepatic stellate cells also express the anti-ﬁbrogenic
adipokine adiponectin which opposes the actions of leptin.
Increased production of leptin and decreased expression of
adiponectin from adipose tissue in the metabolic syndrome pro-
vides a link between obesity and development of ﬁbrosis in
NAFLD.
(16) Apoptosis of activated hepatic stellate cells is a mecha-
nism for achieving resolution of ﬁbrosis [9] and is linked with
regression of ﬁbrotic tissue. AngII stimulates survival of hepatic
stellate cells via an NF-jB-dependent pathway leading to expres-
sion of anti-apoptotic Bcl2 and Gadd45b.
(17) Activated hepatic stellate cells are targeted for apoptosis
by NK cells via a TRAIL-dependent mechanism.
(18) The pro-apoptotic and anti-ﬁbrogenic actions of NK cells
[10] are licensed by TLR3 signalling and dependent on inter-
feron-c, providing one possible explanation for the observed
anti-ﬁbrogenic properties of the interferon.
(19) Another anti-ﬁbrogenic action of interferon-c is repres-
sion of TGFb signalling involving activation of STAT1 and
increased expression of the TGFb inhibitor Smad7. Ethanol
stimulates hepatic stellate cell activation and inhibits NK10 vol. 52 j 949–950
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Fig. 1.
Hepatology Snapshotcytotoxicity against hepatic stellate cells via suppression of IFNc/
STAT1 signalling.
(20) Activated hepatic stellate cells undergo contraction in
response to agonists such as AngII, thus contributing to the patho-
genesis of portal hypertension [1,5]. Contraction of stellate cells is
reverted by other factors such as nitric oxide or carbon monoxide.Conﬂicts of interest
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